Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 59 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.CompletedNCT05130515Phase 2
• A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal CancerStatus unknownNCT05130021Phase 2
• Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative NeoplasmsTerminatedNCT05127174Phase 1
• Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaStatus unknownNCT05124431Phase 2
• An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail PsoriasisCompletedNCT05124080Early Phase 1
• A Study of Orelabrutinib in Patients With ITPStatus unknownNCT05124028Phase 1/2
• Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated CorticosteroidsTerminatedNCT05123040Phase 1/2
• A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial CarcinomaStatus unknownNCT05121363Phase 2
• Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus MethotrexateStatus unknownNCT05121298Phase 3
• Study of Ruxolitinib for Acute and Chronic Graft Versus Host DiseaseCompletedNCT05121142Phase 1
• A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsWithdrawnNCT05120960Phase 1
• A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive, not recruitingNCT05120349Phase 3
• Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT StudyCompletedNCT05117957Phase 2
• Study of HA121-28 in Patients With Non-Small Cell Lung CancerStatus unknownNCT05117658Phase 2
• Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid TumoursCompletedNCT05114668Phase 1
• Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsActive, not recruitingNCT05114421Phase 2
• Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous AblativeActive, not recruitingNCT05113186Phase 2
• A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)CompletedNCT05112952Phase 1
• Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT05111444Phase 2
• TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After ResectionStatus unknownNCT05111366Phase 2
• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid TumorsTerminatedNCT05109975Phase 1
• A Dose Escalation and Food Effect Study of SKLB1028 in Healthy SubjectsCompletedNCT05109663Phase 1
• Surufatinib in Patients With Osteosarcoma and Soft Tissue SarcomaActive, not recruitingNCT05106777Phase 2
• A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCTerminatedNCT05106335Phase 3
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy ParticipantsCompletedNCT05105607Phase 1
• Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe AsthmaCompletedNCT05104892Phase 2
• Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05104801Phase 2
• Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsCompletedNCT05104723Phase 1/2
• Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver TransplantTerminatedNCT05103904Phase 2
• Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyCompletedNCT05101629Phase 2
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Phase 3
• StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
• Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male VolunteersStatus unknownNCT05095337Phase 1
• TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationCompletedNCT05091723Phase 1
• Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to MethotrexateStatus unknownNCT05090410Phase 3
• Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort StudyActive, not recruitingNCT05089916Phase 2
• Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
• Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid TumorsCompletedNCT05088070Phase 1
• Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant MelanomaStatus unknownNCT05087602Phase 2
• Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's SyndromeStatus unknownNCT05087589Phase 2
• A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547Status unknownNCT05086666Phase 1/2
• Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)Status unknownNCT05085054Phase 2
• Tocilizumab Versus Baricitinib in Patients With Severe COVID-19CompletedNCT05082714Not applicable
• Brazilian Lung Immunotherapy StudyCompletedNCT05081674Phase 2
• Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1
• Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT05080621Phase 1/2
• COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
• ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung AdenocarcinomasStatus unknownNCT05079022Phase 1/2
• A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsActive, not recruitingNCT05078931Phase 2
• Open-label Study of Surufatinib in Japanese PatientsCompletedNCT05077384Phase 1/2
• A Study of Lazertinib (JNJ-73841937) in Healthy ParticipantsCompletedNCT05076877Phase 1
• Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingNCT05074810Phase 1/2
• A Study to Evaluate Relative Bioavailability and Food-Effect of HA121-28 Tablet B in Healthy SubjectsCompletedNCT05072535Phase 1
• A Study of SKLB1028 in Patients With Advanced Solid TumorStatus unknownNCT05072522Phase 1
• Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALLTerminatedNCT05071482Phase 4
• Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric CancerStatus unknownNCT05070598Phase 2
• Study of Afatinib in Advanced Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT05070403Phase 2
• Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver MetastasisStatus unknownNCT05070221Phase 1
• A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy SubjectsCompletedNCT05070195Phase 1
• A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy SubjectsStatus unknownNCT05069870Phase 1
• JAK Inhibition in Food AllergyCompletedNCT05069831Phase 1
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707CompletedNCT05068466Phase 1
• A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOxStatus unknownNCT05068206Phase 2
• Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung DiseaseWithdrawnNCT05067517Phase 3
• ACALA-R In Predominantly Demyelinating IgM Mediated NeuropathyActive, not recruitingNCT05065554Phase 2
• Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIBCompletedNCT05063110Phase 2
• Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer PatientsSuspendedNCT05062889Phase 2
• A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Status unknownNCT05061147Phase 1/2
• A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult ParticipantsCompletedNCT05057949Phase 1
• A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05057494Phase 3
• Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19Status unknownNCT05056558Phase 3
• A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerCompletedNCT05055232Phase 1
• RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid TumorsTerminatedNCT05052255Phase 1/2
• A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell LymphomaCompletedNCT05051891Phase 3
• To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced MelanomaStatus unknownNCT05051865Phase 2
• A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult ParticipantsCompletedNCT05051553Phase 1
• A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy PeopleCompletedNCT05050279Early Phase 1
• Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous CellStatus unknownNCT05049681Phase 3
• Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic FunctionWithdrawnNCT05048368Phase 1
• Masitinib in Patients With Symptomatic Mild to Moderate COVID-19Status unknownNCT05047783Phase 2
• A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant TumorsStatus unknownNCT05046847Phase 1
• Pharmacokinetics Study of Famitinib Malate Capsules in Healthy SubjectsCompletedNCT05046808Phase 1
• Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung CancerWithdrawnNCT05045404Phase 2
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
• Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid LeukemiaStatus unknownNCT05042531Not applicable
• Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaActive, not recruitingNCT05041153Early Phase 1
• Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis SuppurativaCompletedNCT05040698Phase 2
• A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyWithdrawnNCT05039736Phase 2
• Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2
• Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid TumorsCompletedNCT05038839Phase 1
• Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Active, not recruitingNCT05038813Phase 2
• A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSLCompletedNCT05036577Phase 1
• Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal CancerStatus unknownNCT05035914Phase 1/2
• Study of Ruxolitinib Cream in Children With Atopic DermatitisCompletedNCT05034822Phase 1
• Food Effect and Mass Balance Study of XZP-3621 TabletsCompletedNCT05034120Phase 1
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
• A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)Active, not recruitingNCT05030506Phase 1
• Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerStatus unknownNCT05030246Phase 2

← Tyrosine Kinase Inhibitors overview